Amgen, Inc. (AMGN) Position Boosted by DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.5% in the third quarter, HoldingsChannel.com reports. The firm owned 888,144 shares of the medical research company’s stock after buying an additional 4,565 shares during the period. Amgen accounts for approximately 1.2% of DekaBank Deutsche Girozentrale’s portfolio, making the stock its 10th largest holding. DekaBank Deutsche Girozentrale’s holdings in Amgen were worth $152,472,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of AMGN. Financial Advisory Service Inc. boosted its position in Amgen by 0.3% in the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after buying an additional 5 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares during the period. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after buying an additional 7 shares during the period. Ballentine Partners LLC boosted its position in Amgen by 0.3% in the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the period. Finally, Hudock Capital Group LLC boosted its position in Amgen by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the period. 78.48% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $185.54 on Wednesday. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market cap of $134,690.00, a price-to-earnings ratio of 16.76, a P/E/G ratio of 2.70 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the business earned $3.02 EPS. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. analysts predict that Amgen, Inc. will post 12.71 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a yield of 2.85%. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 41.55%.
Amgen declared that its board has approved a share repurchase plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
Several research firms have recently issued reports on AMGN. Mizuho set a $192.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, December 22nd. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Royal Bank of Canada decreased their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price objective (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. Amgen presently has an average rating of “Hold” and an average price target of $190.15.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares in the company, valued at $9,888,326.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,225,765 over the last quarter. 0.19% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/amgen-inc-amgn-position-boosted-by-dekabank-deutsche-girozentrale/1810286.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with Analyst Ratings Network's FREE daily email newsletter.